AstraZeneca CEO quits as drug sales tumble

<p>LONDON (Reuters) AstraZenecas arch executive David Brennan is to step down on Jun 1 in an sudden exit after 6 years in a tip job, following rising financier displeasure during a companys performance.
Britains second-biggest drugmaker has suffered steady drug development setbacks, stoking fears about a long-term prospects given a finish faith on medication medicines during a time when rivals have diversified.
The organisation cut a full-year distinction foresee as sales fell 11 percent in a initial quarter, badly blank expectations, and underlying gain forsaken 19 percent, highlighting a need to find new sources of expansion as mixed drug patents expire.
Its shares were down 5.9 percent by 1225 GMT.
AstraZeneca has recently accelerated a gait of deal-making, to move in some-more earnest new drugs from other companies, though Brennan, 58, has been underneath glow from investors for not behaving sooner, heading to calls fro...